All News

The EDQM (European Directorate for the Quality of Medicines and HealthCare) are looking to recruit a Scientific Programme Officer to join the team for a five year period to organise, manage and monitor a number of projects related to Pharmaceutical Care and Anti-Counterfeiting activities with a particular focus on the implementation of the MEDICRIME Convention

Will France’s new socialist president, François Hollande, prove too strong for pharma’s taste? Reflector, Pharm Exec’s EU correspondent, reports.

Recognizing that traditional market forces – namely incentives related to intellectual property and a steady demand for products – have failed in developing countries, the World Health Organization (WHO) asked a member state-nominated group to come up with ways to fund R&D and pay for the treatment of neglected diseases in the world’s poorest nations.

A new report from ZS Associates explores the efficacy and impact of physician incentive compensation on the delivery of quality care; when incentives fall short, so can patient outcomes

While French politics has taken a decisive shift to the left with the election of the country’s first socialist president for 17 years

CBI conference highlights three turnaround strategies to plug the gaps in patient adherence.

Drug shortages, particularly those for sterile injectable drugs, took center stage last year. In response, industry and the federal government, including FDA, took steps to address the problem.

For pharma, simply moving traditional marketing materials and tactics from print to online is not enough-a true digital transition must be interactive to be effective.

Marooned at the Top

Companies know they need regulatory information management. What they don't always know is where to start and how to weave this vital capability across the enterprise.

If you really want to know what’s on a patient’s mind, it’s best to skip the small talk and go straight to the brain waves, as demonstrated by Neuro Insight CEO Pranav Yadav in the lead-off presentation yesterday at Chandler Chicco’s Pioneers in Digital Health conference.

After almost nine years of working at Pharm Exec magazine, it’s time for me to move on.

While the FDA continues to develop its guidance for U.S. biosimilars, including a one-day public hearing on May 11, 2012, the basic legal underpinnings of biosimilars in the U.S. may be under threat, as the Supreme Court debates the healthcare law, a large chunk of which includes provisions for biosimilars.

I’ve been doing this digital thing for some time now. I’ve been part of and witnessed many changes in our digital world.

Last week Human Genome Sciences (HGS) rejected GlaxoSmithKline’s (GSK) unsolicited $2.59 billion bid for HGS or $13 per share.

The business outlook for pharma companies for the rest of 2012 and beyond is mixed, as pharma companies struggle to realign themselves to a new business model that will work.

Worried they might get taken for a ride, university tech transfer offices are beginning to hire ex-pharma and biotech personnel to help negotiate deals with industry.

Medication adherence is an ongoing and serious problem; according to the Center for Health Transformation, the annual cost of patients not taking their medicines as prescribed is nearly $300 billion, with approximately 125,000 patients dying each year due to poor adherence-that’s 342 people every day.

Provisions in the Affordable Care Act (ACA) drove out-of-pocket costs down, while increasing drug spending among 19 to 25-year-olds in 2011, according to research published on Wednesday.

Come Rain or Shine

Amid one of the most divisive eras in our nation’s political history, one thing we can all pretty much agree on is the fact that our stalled economic engine needs a jumpstart.

This June, Californians will be asked whether cigarette smokers should subsidize research to treat diseases related to smoking cigarettes.

A critical drug that has experienced shortages is Genzyme’s Fabrazyme (agalsidase beta), the only enzyme replacement therapy approved in the US for Fabry disease.

UK pharma and biopharma was quick to respond positively to the Chancellor of the Exchequer’s annual Budget speech last week, despite some industry disappointment at a fiscal program widely derided as safe, neutral, and, in Andrew Goodwin of Ernst & Young’s words, “one of the most predictable” of recent times.

In judging the Prometheus patents invalid, the Supreme Court may have shown its hand on the upcoming Myriad Genetics case.